Welcome to our dedicated page for Nika Pharmaceuticals news (Ticker: NIKA), a resource for investors and traders seeking the latest updates and insights on Nika Pharmaceuticals stock.
Nika Pharmaceuticals (NIKA) is a global leader in pharmaceutical research and regulated drug distribution, delivering essential medicines through innovative development and strategic partnerships. This page provides investors and industry professionals with timely updates on the company’s operational milestones and market activities.
Access verified press releases covering clinical trial results, regulatory approvals, and financial performance. Our curated news collection offers insights into manufacturing advancements, global distribution agreements, and quality assurance protocols that define NIKA’s industry position.
Key updates include earnings reports, product pipeline developments, and strategic collaborations with healthcare organizations. Bookmark this page to monitor how Nika Pharmaceuticals navigates complex regulatory environments while expanding access to critical therapies worldwide.
Nika Pharmaceuticals (OTCQB: NIKA) has released a report detailing the therapeutic effects of ITV-1 on volunteers with AIDS, cancer, and other diseases. The report highlights specific cases demonstrating the drug's curative effects and its potential applications beyond AIDS treatment.
In parallel developments, Nika Europe has made a second payment of $195,554 for the vial production line and is finalizing clean room design details. The factory construction is expected to be completed by the end of Q2 2025.
Nika Pharmaceuticals (OTCMKTS: NIKA) has signed a distribution agreement for Nigeria with I.Conntact-Connect on June 11, 2024. This partnership targets a market of 229 million people with a 2.1% HIV prevalence rate. Under the agreement, NIKA will receive €1,980 per ITV-1 set, with two sets required per treatment, potentially generating €7.9 billion in revenue.
The deal aims to address Nigeria's HIV epidemic, where 190,950 new HIV/AIDS infections occur annually, including 41,000 cases among children with access to therapies. CEO Dimitar Savov announced plans to open a satellite office in Nigeria to serve as a hub for West Africa, emphasizing the country's strategic importance to NIKA.
Nika Pharmaceuticals (NIKA) announced plans to become a sustainable business, focusing on pharmaceutical production and profitability. Key developments include constructing three factories for injection drugs, tablets, and dietary supplements.
On May 9, 2024, NIKA acquired a production building valued at $2,045,209 for an injection drug factory, expected to finish by December 31, 2024. A new vial production line is set to produce 18,000 vials per hour, with an annual capacity of 3.5 million sets of ITV-1, generating significant profits.
NIKA's Joint Business Agreement with Immunotech Laboratories BG facilitates the production and distribution of ITV-1, an AIDS treatment, expected to start at 30% capacity in 2025, aiming for 90% by 2026. Distribution agreements cover UAE, Ukraine, Iraq, Jordan, and Syria, with ongoing negotiations for more territories.
NIKA's portfolio includes generic drugs and dietary supplements, with ongoing development and market expansion plans. A comprehensive five-year business plan is being prepared to outline future growth.
Nika Pharmaceuticals, Inc. (NIKA) has acquired a production building and land valued at $2,045,209 in Sofia Province, Bulgaria. The company became the 99.99% owner of Nika Europe, , which holds the production building and land. The facility will house laboratories and a manufacturing facility for drug production. Construction is underway, with plans to begin production in January 2025.
